Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Array of Agents Allow for Treatment Individualization in ROS1+ NSCLC

July 27th 2025

Jorge J. Nieva, MD, compares treatment options for patients with ROS1-positive non–small cell lung cancer.

Dr Reckamp on the Future Implications of the PRAGMATICA-LUNG Trial in Lung Cancer

July 26th 2025

Karen L. Reckamp, MD, discusses the feasibility of future pragmatic clinical trials for patients with lung cancer.

Dr Das on Updates to the Standard First-Line Treatment Paradigm for ES-SCLC

July 26th 2025

Millie Das, MD, discusses first-line standards of care for patients with extensive-stage and limited-stage small cell lung cancer.

Novel Approaches Offer the Potential to Combat Immunotherapy–Refractory NSCLC

July 26th 2025

Hossein Borghaei, DO, MS, discusses novel approaches to overcoming immunotherapy resistance in patients with non–small cell lung cancer.

The OncFive: Top Oncology Articles for the Week of 7/20

July 26th 2025

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

New Immunotherapy Regimens Aim to Build Upon Durvalumab in Locally Advanced NSCLC

July 26th 2025

Marina C. Garassino, MD, discusses the standing of durvalumab and other immunotherapy-based approaches in locally advanced NSCLC.

Dr Jänne on Second-Line Treatment Evolutions in EGFR-Mutated NSCLC

July 25th 2025

Pasi A. Jänne, MD, PhD, discusses changes to the second-line treatment paradigm and treatment decision-making factors for patients with EGFR-mutated NSCLC.

Personalizing Treatment for Atypical EGFR-Mutated NSCLC

July 25th 2025

Sukhmani Padda, MD, discusses ways in which evolving treatment paradigms are tailoring treatment to target atypical EGFR alterations in NSCLC.

Dr Mok on Choosing Between First-Line Therapies for BRAF-Mutant NSCLC

July 25th 2025

Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, discusses first-line treatment decision-making for patients with BRAF-mutant non–small cell lung cancer.

Understanding Underlying Resistance Mechanisms is Vital for Guiding Treatment Selection Post-Osimertinib in EGFR+ NSCLC

July 25th 2025

Heather Wakelee, MD, discusses underlying resistance mechanisms and potential therapies for EGFR+ NSCLC following osimertinib.

Updated Findings From CheckMate-816 for Neoadjuvant Nivolumab Plus Chemo in Resectable NSCLC

July 24th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated findings for neoadjuvant nivolumab plus chemotherapy in resectable NSCLC.

Surgical Outcomes From CheckMate-77T With Perioperative Nivolumab in Resectable NSCLC

July 24th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss surgical outcomes from CheckMate-77T for perioperative nivolumab in resectable NSCLC.

Elironrasib Receives FDA Breakthrough Therapy Designation for Pretreated KRAS G12C+ NSCLC

July 24th 2025

The FDA has granted breakthrough therapy designation to elironrasib for KRAS G12C–mutated advanced NSCLC previously treated with chemotherapy and immunotherapy.

Dr Nieva on the Rationale for Comparing ALK Inhibitors in ALK+ NSCLC

July 24th 2025

Jorge Nieva, MD, discusses matched-adjusted indirect comparison data evaluating crizotinib vs alectinib, brigatinib, and lorlatinib in ALK-positive NSCLC.

Dr Patel on Toxicities Associated With Immunotherapy-Based Combinations in NSCLC

July 23rd 2025

Sandip P. Patel, MD, discusses toxicities associated with the use of immunotherapy-based combination regimens in patients with advanced NSCLC.

Dr Shum on Evolving First-Line Treatment Approaches for EGFR-Mutant NSCLC

July 23rd 2025

Elaine Shum, MD, discusses questions that remain regarding the first-line treatment paradigm for patients with EGFR-mutant non–small cell lung cancer.

Dr Donington on the Evolving Use of Perioperative Nivolumab in Resectable NSCLC

July 22nd 2025

Jessica Donington, MD, MSCR, discusses how updated data with perioperative nivolumab in NSCLC may affect future surgical decision-making.

FDA Grants Fast Track Designation to Next-Generation HER3-Directed ADC for EGFR+ Advanced NSCLC

July 22nd 2025

The FDA granted fast track designation to DB-1310 for patients with pretreated, advanced non–small cell lung cancer harboring select EGFR mutations.

Accelerating US Oncology Drug Development Using Chinese First-in-Human Data

July 22nd 2025

Evan S. Wu, Md, PhD, concludes a three-part series highlighting the translatability of Chinese clinical data into US regulatory pathways.

FDA Green-Lights Subcutaneous Nivolumab: What It Means for Early-Stage NSCLC Care

July 22nd 2025

Panelists discuss how subcutaneous (SQ) nivolumab administration offers patient convenience and potential logistical advantages, particularly in the maintenance setting, though they acknowledge limited current adoption and need for more biological data on efficacy differences.